ClinicaliQ Trial Snapshot
- Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics — Active Not Recruiting • Phase IV • Respiratory / COPD / Asthma • NCT03953300.
- Benralizumab improves lung structure and function in severe eosinophilic asthma poorly controlled by standard inhalers.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period. Conditions: Asthma Interventions: Benralizumab, Placebo Lead Sponsor: AstraZeneca Planned Enrollment: 75 participants